Spots Global Cancer Trial Database for il2
Every month we try and update this database with for il2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | NCT02919644 | Stage IV Colore... Curative Resect... | autologous dend... IL2 | 19 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company | |
| Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | NCT02919644 | Stage IV Colore... Curative Resect... | autologous dend... IL2 | 19 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | NCT00283829 | Prostate Cancer | docetaxel IL2 | 18 Years - | University of Washington | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation | NCT01517347 | Leukemia | Interleukin-2 | 15 Years - 65 Years | Peking University People's Hospital | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company | |
| Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | NCT00283829 | Prostate Cancer | docetaxel IL2 | 18 Years - | University of Washington | |
| Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer | NCT00582790 | Kidney Cancer | IL2 Zoledronic acid | 18 Years - | University of Wisconsin, Madison | |
| Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | NCT00283829 | Prostate Cancer | docetaxel IL2 | 18 Years - | University of Washington | |
| Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer | NCT00582790 | Kidney Cancer | IL2 Zoledronic acid | 18 Years - | University of Wisconsin, Madison | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
